Newcelx LTD. (NCEL) — 6-K Filings

All 6-K filings from Newcelx LTD.. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

6-K Filing — Apr 20, 2026
NewcelX Ltd. Files 6-K with Purchase Agreements and Warrants — Apr 1, 2026 Risk: medium
NewcelX Ltd. filed a Form 6-K on April 1, 2026, reporting a Securities Purchase Agreement dated April 1, 2026. The filing includes exhibits detailing the form o
6-K Filing — Dec 11, 2025
6-K Filing — Nov 20, 2025
NewcelX Ltd. Adds Top Neurologist to Scientific Advisory Board — Nov 17, 2025 Risk: low
On November 17, 2025, NewcelX Ltd. announced the appointment of Dr. Jeremy Shefner, Chief Medical Officer at the Barrow Neurological Institute, to its Scientifi
6-K Filing — Nov 7, 2025
NewcelX Ltd. CEO Issues Letter to Shareholders — Nov 4, 2025 Risk: low
On November 4, 2025, NewcelX Ltd. (formerly NLS Pharmaceutics Ltd.) issued a press release containing a letter from its CEO to shareholders. The company, incorp
6-K Filing — Nov 3, 2025
NLS Pharma Expands CNS Pipeline with Aexon Labs' AEX-6xx Series — Oct 30, 2025 Risk: medium
On October 30, 2025, NLS Pharmaceutics Ltd. announced an expansion of its Central Nervous System (CNS) pipeline through the acquisition of the AEX-6xx series of
NLS Pharmaceutics Merges Subsidiary with Kadimastem — Oct 29, 2025 Risk: medium
On November 4, 2024, NLS Pharmaceutics Ltd. announced a merger agreement where its subsidiary, NLS Pharmaceutics (Israel) Ltd., will merge with Kadimastem Ltd.
NLS Pharmaceutics & Kadimastem Merger Conditions Met — Oct 28, 2025 Risk: medium
On October 28, 2025, NLS Pharmaceutics Ltd. announced the completion of material conditions precedent for its merger with Kadimastem. This announcement also con
NLS Pharmaceutics Partners for Gene-Edited Cell Therapies — Oct 27, 2025 Risk: medium
On October 27, 2025, NLS Pharmaceutics Ltd. announced a strategic collaboration between its subsidiary TargetGene and Kadimastem. This partnership aims to advan
NLS Pharmaceutics & Kadimastem Merger Gets Nasdaq Nod — Oct 23, 2025 Risk: medium
NLS Pharmaceutics Ltd. announced on October 23, 2025, that they received Nasdaq approval for their merger with Kadimastem. The merger is anticipated to close on
NLS Pharmaceutics Ltd. Merges with Kadimastem Ltd. — Oct 10, 2025 Risk: medium
NLS Pharmaceutics Ltd. announced on October 10, 2025, that its wholly owned subsidiary, NLS Pharmaceutics (Israel) Ltd., entered into a Merger Agreement with Ka
NLS Pharmaceutics Files Interim Financials — Oct 6, 2025 Risk: low
NLS Pharmaceutics Ltd. filed an Unaudited Interim Condensed Financial Statement on October 6, 2025, for the period ending June 30, 2025. This report includes fi
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem — Sep 30, 2025 Risk: medium
On September 30, 2025, NLS Pharmaceutics Ltd. announced that its shareholders approved the merger with Kadimastem and related proposals at an Extraordinary Gene
NLS Pharmaceutics Auditor Resigns Amidst Business Acquisition — Sep 19, 2025 Risk: medium
NLS Pharmaceutics Ltd. was notified by its auditor, Marcum LLP, on September 17, 2025, that Marcum will resign immediately. This resignation is a result of CBIZ
NLS Pharmaceutics Merger Registration Statement Effective — Sep 10, 2025 Risk: medium
On September 10, 2025, NLS Pharmaceutics Ltd. announced that the SEC registration statement related to its proposed merger with Kadimastem has become effective.
NLS Pharmaceutics Secures Hong Kong Patent for Diabetes Tech — Sep 4, 2025 Risk: medium
On September 4, 2025, NLS Pharmaceutics Ltd. announced a patent granted in Hong Kong for cell-selection and enrichment technology related to its IsletRx product
NLS Pharmaceutics Amends Merger Agreement for Seventh Time — Aug 29, 2025 Risk: medium
On August 29, 2025, NLS Pharmaceutics Ltd. entered into the Seventh Amendment to its Merger Agreement, originally dated November 4, 2024. This marks the seventh
NLS Pharmaceutics Reschedules Shareholder Meeting for Kadimastem Deal — Aug 25, 2025 Risk: medium
NLS Pharmaceutics Ltd. announced on August 21, 2025, that it has rescheduled its Extraordinary Shareholders' Meeting, originally set for August 25, 2025. The me
NLS Pharmaceutics Exchanges Warrants with Alpha Capital — Aug 6, 2025 Risk: medium
On August 5, 2025, NLS Pharmaceutics Ltd. entered into a warrant exchange agreement with Alpha Capital Anstalt. This agreement involves the exchange of a common
NLS Pharmaceutics Amends Merger Agreement for Sixth Time — Jul 18, 2025 Risk: medium
On July 18, 2025, NLS Pharmaceutics Ltd. entered into a sixth amendment to its Merger Agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This am
NLS Pharma diabetes therapy gets BIRD Foundation milestone payment — Jul 17, 2025 Risk: medium
On June 17, 2025, NLS Pharmaceutics Ltd. announced that the BIRD Foundation approved an additional milestone payment to Kadimastem and iTolerance for the co-dev
NLS Pharmaceutics Amends Merger Agreement Again — Jul 1, 2025 Risk: medium
On July 1, 2025, NLS Pharmaceutics Ltd. entered into the Fifth Amendment to its Merger Agreement, originally dated November 4, 2024. This amendment modifies the
NLS Pharmaceutics Amends Private Placement Agreement — Jun 30, 2025 Risk: low
On June 26, 2025, NLS Pharmaceutics Ltd. amended its Securities Purchase Agreement from March 27, 2025, related to a private placement. The initial closing unde
NLS Pharmaceutics CEO Letter to Shareholders Filed — Jun 16, 2025 Risk: low
On June 16, 2025, NLS Pharmaceutics Ltd. issued a press release containing a letter from its CEO to shareholders. The press release is furnished as Exhibit 99.1
NLS Pharmaceutics Schedules June 30th Annual Shareholder Meeting — Jun 10, 2025 Risk: low
NLS Pharmaceutics Ltd. filed a Form 6-K on June 10, 2025, announcing its Annual General Shareholders' Meeting scheduled for June 30, 2025. Shareholders of recor
NLS Pharmaceutics Amends Merger Agreement for Fourth Time — Jun 6, 2025 Risk: medium
On June 5, 2025, NLS Pharmaceutics Ltd. entered into a fourth amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel)
NLS Pharmaceutics Amends Merger Agreement with Kadimastem — May 5, 2025 Risk: medium
On May 5, 2025, NLS Pharmaceutics Ltd. entered into a third amendment to its Merger Agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amen
NLS Pharmaceutics Director Resigns — Apr 24, 2025 Risk: low
On April 18, 2025, Audrey Greenberg resigned from the Board of Directors of NLS Pharmaceutics Ltd. Her resignation was effective immediately and was not due to
NLS Pharmaceutics: Mazindol Shows Promise Against Fentanyl Reward — Apr 15, 2025 Risk: medium
On April 15, 2025, NLS Pharmaceutics Ltd. announced positive results from its Study KO-943. The study demonstrated that Mazindol, a drug developed by the compan
NLS Pharmaceutics Raises $3M in Private Placement — Mar 31, 2025 Risk: medium
On March 27, 2025, NLS Pharmaceutics Ltd. entered into a securities purchase agreement with three accredited investors for a private placement offering. The com
NLS Pharmaceutics CEO Letter to Shareholders Filed — Mar 10, 2025 Risk: low
On March 10, 2025, NLS Pharmaceutics Ltd. issued a press release containing a letter from its CEO to shareholders. The filing itself is a Form 6-K, which is a r
NLS Pharmaceutics: AEX-2 Preclinical Data Shows Promise — Feb 27, 2025 Risk: medium
On February 27, 2025, NLS Pharmaceutics Ltd. announced new preclinical data for its AEX-2 compound. This data suggests an expanded therapeutic potential for the
NLS Pharmaceutics Subs Complete FDA Pre-IND Meeting for Diabetes Drug — Feb 25, 2025 Risk: medium
On February 25, 2025, NLS Pharmaceutics Ltd. announced that its subsidiaries Kadimastem and iTolerance successfully completed a Pre-IND meeting with the U.S. Fo
NLS Pharma & Kadimastem Target Diabetes Beyond GLP-1 — Feb 10, 2025 Risk: medium
On February 10, 2025, NLS Pharmaceutics Ltd. announced a collaboration with Kadimastem to develop a multi-target approach for diabetes treatment, moving beyond
NLS Pharmaceutics and Kadimastem Merger Approved — Jan 31, 2025 Risk: medium
On January 31, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem shareholders approved the merger with NLS Pharmaceutics. This filing incorporates the pres
NLS Pharmaceutics Submits Abstracts to ASCP Meeting — Jan 30, 2025 Risk: low
On January 30, 2025, NLS Pharmaceutics Ltd. announced the submission of three research abstracts to the 2025 ASCP Annual Meeting. This filing incorporates the p
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence — Jan 28, 2025 Risk: medium
On January 28, 2025, NLS Pharmaceutics Ltd. announced the initiation of a preclinical program for its drug Mazindol ER, aimed at treating fentanyl dependence. T
NLS Pharmaceutics Merger Vote Scheduled — Jan 16, 2025 Risk: medium
On January 16, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem has called for a Special General Meeting of Shareholders to approve a merger with NLS. Thi
NLS Pharmaceutics Shareholders Approve All Agenda Items — Jan 14, 2025 Risk: low
On January 14, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved. This report is incorporat
NLS Pharmaceutics Closes $500K Fundraising at Premium — Jan 8, 2025 Risk: medium
NLS Pharmaceutics Ltd. announced on January 8, 2025, the initial closing of a $500,000 fundraising, part of a previously announced $1 million total. This fundra
NLS Pharmaceutics Shareholders Approve Most Proposals — Jan 7, 2025 Risk: low
On January 7, 2025, NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting where all proposed agenda items were approved, except for Proposal 6, whi
NLS Pharma & Kadimastem File F-4 for Merger — Dec 30, 2024 Risk: medium
On December 30, 2024, NLS Pharmaceutics Ltd. announced the filing of an F-4 registration statement with the SEC. This filing is in anticipation of a proposed me
NLS Pharmaceutics Schedules Shareholder Meeting for Jan 14 — Dec 23, 2024 Risk: low
NLS Pharmaceutics Ltd. has scheduled an Extraordinary Shareholders' Meeting for January 14, 2025. Shareholders of record as of December 23, 2024, will be eligib
NLS Pharma & Kadimastem Seek FDA Meeting for Diabetes Treatment — Dec 19, 2024 Risk: medium
On December 19, 2024, NLS Pharmaceutics Ltd. announced that its partner Kadimastem and its subsidiary iTolerance, Inc. have submitted a request to the FDA for a
NLS Pharmaceutics Schedules Shareholder Meeting for Jan 7 — Dec 17, 2024 Risk: low
NLS Pharmaceutics Ltd. announced an Extraordinary Shareholders' Meeting scheduled for January 7, 2025. Shareholders of record as of December 16, 2024, are eligi
NLS Pharmaceutics CEO Letter to Shareholders Filed — Dec 11, 2024 Risk: low
On December 11, 2024, NLS Pharmaceutics Ltd. filed a Form 6-K to report the issuance of a press release. This press release, titled "NLS Pharmaceutics CEO Issue
NLS Pharmaceutics Ltd. Announces Private Placement — Dec 4, 2024 Risk: medium
On December 4, 2024, NLS Pharmaceutics Ltd. entered into a securities purchase agreement for a private placement offering. The company agreed to issue and sell

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX